Premium
In Vivo 31 P magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts
Author(s) -
Esmaeili Morteza,
Moestue Siver A.,
Hamans Bob C.,
Veltien Andor,
Kristian Alexandr,
Engebråten Olav,
Mælandsmo Gunhild M.,
Gribbestad Ingrid S.,
Bathen Tone F.,
Heerschap Arend
Publication year - 2015
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.24588
Subject(s) - phosphocholine , in vivo , magnetic resonance spectroscopic imaging , choline , breast cancer , magnetic resonance imaging , metabolite , pathology , cancer , malignancy , cancer research , nuclear magnetic resonance , biology , chemistry , phospholipid , medicine , phosphatidylcholine , biochemistry , radiology , physics , microbiology and biotechnology , membrane
Purpose To study cancer associated with abnormal metabolism of phospholipids, of which several have been proposed as biomarkers for malignancy or to monitor response to anticancer therapy. We explored 3D 31 P magnetic resonance spectroscopic imaging (MRSI) at high magnetic field for in vivo assessment of individual phospholipids in two patient‐derived breast cancer xenografts representing good and poor prognosis (luminal‐ and basal‐like tumors). Materials and Methods Metabolic profiles from luminal‐like and basal‐like xenograft tumors were obtained in vivo using 3D 31 P MRSI at 11.7T and from tissue extracts in vitro at 14.1T. Gene expression analysis was performed in order to support metabolic differences between the two xenografts. Results In vivo 31 P MR spectra were obtained in which the prominent resonances from phospholipid metabolites were detected at a high signal‐to‐noise ratio (SNR >7.5). Metabolic profiles obtained in vivo were in agreement with those obtained in vitro and could be used to discriminate between the two xenograft models, based on the levels of phosphocholine, phosphoethanolamine, glycerophosphocholine, and glycerophosphoethanolamine. The differences in phospholipid metabolite concentration could partly be explained by gene expression profiles. Conclusion Noninvasive metabolic profiling by 3D 31 P MRSI can discriminate between subtypes of breast cancer based on different concentrations of choline‐ and ethanolamine‐containing phospholipids. J. Magn. Reson. Imaging 2015;41:601–609. © 2014 Wiley Periodicals, Inc.